Video

Dr. Yurgelun on Educating Patients on Genetic Testing for CRC

Matthew Yurgelun, MD, instructor in medicine, Harvard Medical School, Dana-Farber Cancer Institute, explains why oncologists should discuss genetic testing with their patients and family members for colorectal cancer, as well as some of the common risk factors for the disease.

Matthew Yurgelun, MD, instructor in medicine, Harvard Medical School, Dana-Farber Cancer Institute, explains why oncologists should discuss genetic testing with their patients and family members for colorectal cancer (CRC), as well as discusses a common risk factor for the disease.

There is great interest in testing tumor specimens to discover driver mutations that could be treated with targeted therapies, Yurgelun explains. However, it is important to also study germline DNA in order to gain a deeper understanding of an individual patient's cause of disease and whether their family members are at risk for developing CRC.

A common risk factor for developing CRC is family history, especially in the setting of Lynch syndrome. For patients with a family history of CRC, Yurgelun advises that they be screened earlier and more frequently.

Related Videos
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS
Charles E. Geyer, Jr., MD
Sattva S. Neelapu, MD